Amanda E. Toland

19.1k total citations · 1 hit paper
97 papers, 2.9k citations indexed

About

Amanda E. Toland is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Amanda E. Toland has authored 97 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Genetics, 37 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in Amanda E. Toland's work include BRCA gene mutations in cancer (32 papers), Genomics and Rare Diseases (15 papers) and Nonmelanoma Skin Cancer Studies (14 papers). Amanda E. Toland is often cited by papers focused on BRCA gene mutations in cancer (32 papers), Genomics and Rare Diseases (15 papers) and Nonmelanoma Skin Cancer Studies (14 papers). Amanda E. Toland collaborates with scholars based in United States, United Kingdom and Switzerland. Amanda E. Toland's co-authors include Amy M. Dworkin, Khalid Mounzih, Jun Qiu, Farid Chehab, Allan Balmain, Ümit V. Çatalyürek, Tim H-M. Huang, O. Hans Iwenofu, Jessica L. Fleming and Doruk Bozdağ and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Amanda E. Toland

93 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacogenomics: Driving Personalized Medicine

2023 86 citations Wolfgang Sadée, Daqing Wang et al. Pharmacological Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda E. Toland United States	31	1.3k	824	728	443	438	97	2.9k
William E. Russell United States	37	2.2k 1.7×	1.1k 1.4×	1.4k 1.9×	556 1.3×	648 1.5×	90	6.3k
Aritoshi Iida Japan	33	2.1k 1.6×	1.5k 1.8×	789 1.1×	413 0.9×	415 0.9×	126	4.5k
Lam C. Tsoi United States	37	1.4k 1.0×	310 0.4×	494 0.7×	370 0.8×	324 0.7×	155	4.3k
Hyun Sub Cheong South Korea	30	1.0k 0.8×	639 0.8×	268 0.4×	247 0.6×	419 1.0×	163	2.9k
Hugh M. Davis United States	39	1.2k 0.9×	1.4k 1.7×	712 1.0×	129 0.3×	1.0k 2.4×	93	5.0k
Hans‐Peter Fischer Germany	36	816 0.6×	271 0.3×	958 1.3×	399 0.9×	902 2.1×	137	3.6k
Christopher I. Amos United States	42	2.2k 1.7×	1.8k 2.1×	869 1.2×	682 1.5×	520 1.2×	101	6.1k
Amanda Nichols United States	16	1.4k 1.1×	482 0.6×	670 0.9×	942 2.1×	498 1.1×	27	4.3k
Jessica A. Wofford United States	18	1.0k 0.8×	259 0.3×	505 0.7×	515 1.2×	318 0.7×	20	2.8k
Osamu Wada‐Hiraike Japan	35	1.1k 0.9×	361 0.4×	481 0.7×	412 0.9×	325 0.7×	161	3.4k

Countries citing papers authored by Amanda E. Toland

Since Specialization

Citations

This map shows the geographic impact of Amanda E. Toland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda E. Toland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda E. Toland more than expected).

Fields of papers citing papers by Amanda E. Toland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda E. Toland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda E. Toland. The network helps show where Amanda E. Toland may publish in the future.

Co-authorship network of co-authors of Amanda E. Toland

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda E. Toland. A scholar is included among the top collaborators of Amanda E. Toland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda E. Toland. Amanda E. Toland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hanenberg, Helmut, Constanze Wiek, Brett Klamer, et al.. (2025). Reclassification of ATM Missense Variants of Uncertain Significance by Integrating Results from Systematic Functional Assays into an ACMG Points–Based Framework. Clinical Cancer Research. 31(12). 2426–2440.

Shi, Ni, Rhea Harewood, Amanda E. Toland, et al.. (2025). Insulinemic and inflammatory dietary patterns and colorectal cancer risk: a dietary data harmonization study of one million participants in the Consortium of Metabolomics Studies (COMETS). American Journal of Clinical Nutrition. 123(1). 101099–101099.

Alves, Michele Joana, Brigitte Browe, Wesley Wang, et al.. (2024). Metabolic trade-offs in Neonatal sepsis triggered by TLR4 and TLR1/2 ligands result in unique dysfunctions in neural breathing circuits. Brain Behavior and Immunity. 119. 333–350. 4 indexed citations

Sadée, Wolfgang, Daqing Wang, Katherine E. Hartmann, & Amanda E. Toland. (2023). Pharmacogenomics: Driving Personalized Medicine. Pharmacological Reviews. 75(4). 789–814. 86 indexed citations breakdown →

Byrne, Lindsey & Amanda E. Toland. (2021). Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening. Urologic Clinics of North America. 48(3). 387–399. 8 indexed citations

Solano, Ángela R., Edenir Inêz Palmero, Lucı́a Delgado, et al.. (2020). Sequencing technology status of BRCA1/2 testing in Latin American Countries. npj Genomic Medicine. 5(1). 22–22. 2 indexed citations

Nagarajan, Priyadharsini, Maryam M. Asgari, Adèle C. Green, et al.. (2019). Keratinocyte Carcinomas: Current Concepts and Future Research Priorities. Clinical Cancer Research. 25(8). 2379–2391. 93 indexed citations

Sturm, Amy C., Tara Schmidlen, Laura Scheinfeldt, et al.. (2018). Early Outcome Data Assessing Utility of a Post-Test Genomic Counseling Framework for the Scalable Delivery of Precision Health. Journal of Personalized Medicine. 8(3). 25–25. 9 indexed citations

Schmidlen, Tara, Amy C. Sturm, Shelly R. Hovick, et al.. (2018). Operationalizing the Reciprocal Engagement Model of Genetic Counseling Practice: a Framework for the Scalable Delivery of Genomic Counseling and Testing. Journal of Genetic Counseling. 27(5). 1111–1129. 22 indexed citations

10.

Sweet, Kevin, Amy C. Sturm, Tara Schmidlen, et al.. (2017). Outcomes of a Randomized Controlled Trial of Genomic Counseling for Patients Receiving Personalized and Actionable Complex Disease Reports. Journal of Genetic Counseling. 26(5). 980–998. 17 indexed citations

11.

Lowenstein, Stefan E., Giorgia L. Garrett, Amanda E. Toland, et al.. (2017). Risk prediction tools for keratinocyte carcinoma after solid organ transplantation: a review of the literature. British Journal of Dermatology. 177(5). 1202–1207. 17 indexed citations

12.

Braggio, Danielle, Amanda E. Toland, Raphael E. Pollock, et al.. (2016). TGF-β and CTGF are Mitogenic Output Mediators of Wnt/β-Catenin Signaling in Desmoid Fibromatosis. Applied immunohistochemistry & molecular morphology. 25(8). 559–565. 12 indexed citations

13.

Sweet, Kevin, Shelly R. Hovick, Amy C. Sturm, et al.. (2016). Counselees’ Perspectives of Genomic Counseling Following Online Receipt of Multiple Actionable Complex Disease and Pharmacogenomic Results: a Qualitative Research Study. Journal of Genetic Counseling. 26(4). 738–751. 16 indexed citations

14.

Toland, Amanda E., et al.. (2015). Variants in an Hdac9 intronic enhancer plasmid impact Twist1 expression in vitro. Mammalian Genome. 27(3-4). 99–110. 4 indexed citations

15.

Lea, C. Suzanne, et al.. (2014). Melanoma Incidence Rates in Active Duty Military Personnel Compared With a Population-Based Registry in the United States, 2000–2007. Military Medicine. 179(3). 247–253. 22 indexed citations

16.

Fleming, Jessica L., et al.. (2013). Differential expression of miR-1 , a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice. PeerJ. 1. e68–e68. 18 indexed citations

17.

Fleming, Jessica L., Amy M. Dworkin, Dawn C. Allain, et al.. (2013). Allele‐specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma. International Journal of Cancer. 134(1). 244–248. 12 indexed citations

18.

Chiba, Natsuko, et al.. (2010). Identification of Breast Tumor Mutations in BRCA1 That Abolish Its Function in Homologous DNA Recombination. Cancer Research. 70(3). 988–995. 96 indexed citations

19.

Chen, Ying, Amanda E. Toland, Jane McLennan, et al.. (2006). Lack of Germ-Line Promoter Methylation in BRCA1 -Negative Families with Familial Breast Cancer. Genetic Testing. 10(4). 281–284. 19 indexed citations

20.

Mounzih, Khalid, Jun Qiu, Amanda E. Toland, & Farid Chehab. (1998). Leptin Is Not Necessary for Gestation and Parturition But Regulates Maternal Nutrition via a Leptin Resistance State. Endocrinology. 139(12). 5259–5262. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact